-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Disitamab Vedotin in Kidney Cancer (Renal Cell Cancer)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Disitamab Vedotin in Kidney Cancer (Renal Cell Cancer) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Disitamab Vedotin in Kidney Cancer (Renal Cell Cancer)...
-
Track & Monitor
Immuno-oncology in Pharmaceuticals: Microbiota restoration therapy
Innovation in the pharmaceuticals industry is relentless, making it hard to stay-on top of the dynamically evolving industry landscape and in early identification of profound shifts, posing high risk of being disrupted if detected too late. GlobalData's coherent data-driven approach, using multiple forward-looking alternative datasets, empowers clients by decoding in advance the disruptive innovations in pharmaceuticals industry. Using patents data, GlobalData's proprietary industry innovation s-curve identifies specific innovation areas and their stage of evolution, i.e., whether they are emerging, accelerating...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – RBX-7455
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry RBX-7455 Drug Details RBX-7455 is under development for the prevention of Clostridium difficile infections,...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – RBX-2660
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry RBX-2660 Drug Details RBX-2660 is under development for the treatment of Crohn's disease, recurrent...
-
Report Bundle
26% offTrends in Pharma – Report Bundle (4 Reports)
‘The pharmaceutical sector is witnessing a massive revamp. It has been conventionally slow in the adoption of technology and is now undergoing rapid changes due to the development of several technologies as well as innovations. From modern cancer research facilities to gene treatment centers, the novel association between the human mind and technology has become a self-evolving matter. Post-COVID, equipped with cutting-edge technology, the prominent pharma industry tends to invest increasingly in inter-organizational collaborations to boost a favorable environment for...
-
Report Bundle
50% offInnovations in Pharma – Report Bundle (5 Reports)
Innovations in Pharma Bundle Report Overview The healthcare industry constantly demands innovation, improvement, accessibility, and affordability. The ‘Innovations in Pharma’ bundle highlights the emerging drug development technologies in providing quality healthcare services. Accessing the in-depth insight from the Innovations in Pharma bundle can help you: Make informed decisions about investments, partnerships, and product development Understand your competitors’ strengths and weaknesses, identify areas of opportunity, and develop strategies to stay ahead in the market Anticipate market changes and adjust your strategies accordingly...
-
Product Insights
Vancomycin-Resistant Enterococcus Faecium Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
The Vancomycin-Resistant Enterococcus Faecium Infections pipeline drugs market research report provides comprehensive information on the therapeutics under development for Vancomycin-Resistant Enterococcus Faecium Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report reviews key players involved in therapeutic development for...
-
Product Insights
Clostridioides Difficile Infections (Clostridium Difficile Associated Disease) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Clostridioides difficile Infections – Drugs In Development, 2022, provides an overview of the Clostridioides difficile Infections (Infectious Disease) pipeline landscape. Clostridium difficile infections are caused by Clostridium difficile, often called C. difficile or C. diff, a bacterium that can cause symptoms ranging from diarrhea to life-threatening inflammation of the colon. Symptoms of C. diff infection includes watery diarrhea, with abdominal pain or tenderness, loss of appetite, fever, blood or pus...
-
Product Insights
Ulcerative Colitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Ulcerative Colitis – Drugs In Development, 2022, provides an overview of the Ulcerative Colitis (Gastrointestinal) pipeline landscape. Ulcerative Colitis (Colitis ulcerosa or UC) is a chronic disease mainly of the large intestine or colon and a type of Inflammatory Bowel Disease (IBD). The disease is characterized by open sores and ulcers in the colon. The risk factors for UC include smoking, family history of the disease, liver disease, colon cancer,...
-
Thematic Analysis
Microbiome-Targeting Therapeutics in Infectious Diseases – Thematic Research
Microbiome is the community of microorganisms such as fungi, bacteria, and viruses, and their genetic material existing in and on the human body. Although the primary site of aggregated microbes is in the gastrointestinal (GI) tract, populations of microorganisms are also found on the surface of the skin, in the upper and lower respiratory tract, and in the genitourinary tracts. Microbiome-targeting drugs aim to alter the microbial composition of the gut through the administration of live microbes (probiotics), or other...